What is Jakafi?
Jakafi® (ruxolitinib) (JAK-ah-fye) is a prescription medicine available as a pill. It is used to treat adults with polycythemia vera (polly-sigh-THEE-me-ah VAIR-ah), or PV, who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Jakafi is the first and only medicine approved by the Food and Drug Administration (FDA) for the treatment of these patients.
Jakafi is not chemotherapy. It is a targeted treatment that works to help keep the production of blood cells under control.
Explore possible benefits
Discover what may be possible with Jakafi for the treatment of polycythemia vera in patients who did not benefit from HU.
How does Jakafi work?
Polycythemia vera (PV) is a complex condition, and researchers are still trying to discover its exact cause. Evidence suggests that proteins known as Janus kinases, or JAKs, are involved. JAK proteins send signals that affect the production of blood cells in the bone marrow (A). When JAKs send too many signals, they cause the body to make the wrong number of blood cells. This chain of events is called overactive JAK signaling (B).
JAK signaling may become overactive in many ways. One way is by a JAK mutation. A mutation is a small change in the DNA that causes proteins to act differently than normally intended. All people with PV are believed to have overactive JAK signaling even if they do not have a JAK mutation.
Jakafi is a targeted therapy that works by targeting JAKs, which control the production of blood cells. In doing so, Jakafi helps to reduce overactive JAK signaling to help keep the production of blood cells under control